[5-(3-BROMOPHENYL)-4,5-DIHYDRO-3-(NAPHTH-2-YL)-1HPYRAZOL-1-YL]-ETHANONE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	MFWWMGIYQKDADU-UHFFFAOYSA-N
Smiles	Brc1cccc(c1)C2CC(=NN2CC=O)c3ccc4ccccc4c3
InChI	InChI=1S/C21H17BrN2O/c22-19-7-3-6-18(13-19)21-14-20(23-24(21)10-11-25)17-9-8-15-4-1-2-5-16(15)12-17/h1-9,11-13,21H,10,14H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C21H17BrN2O
Molecular Weight	393.28
AlogP	4.25
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	4.0
Polar Surface Area	32.67
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	25.0

Assay Description	Organism	Bioactivity
Cytotoxicity against Homo sapiens (human) Hep2 cells after 48 hr by SRB assay	Homo sapiens	8780.0 nM
Cytotoxicity against Homo sapiens (human) IMR32 cells after 48 hr by SRB assay	Homo sapiens	9870.0 nM
Cytotoxicity against Homo sapiens (human) OVCAR cells after 48 hr by SRB assay	Homo sapiens	10780.0 nM
Cytotoxicity against Homo sapiens (human) PC3 cells after 48 hr by SRB assay	Homo sapiens	10880.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL2237903
PubChem	76308203

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).